Who we areWe are an interdisciplinary team leading a transformative approach to drug R&D based on the modeling of complex biological systems
#drugR&D #insilicomedicine #clinicalresearchmethodology #systemsbiology #machinelearning
People and Culture
Our people are our greatest asset
We nurture a highly collaborative and anti-disciplinary environment and provide chances to grow rapidly as evidenced by our choice to give client facing and project management responsibilities early in your career.
We set the highest standards for ourselves to deliver actionable insights to our clients and ultimately improve the life of patients suffering from serious conditions.
Co-founder & Chief Executive Officer
Co-founder & Chief Scientific Officer
Co-founder & Chief Technology Officer
General Director of the Centre Leon Berard
Partner & Managing Director at Boston Consulting Group
Part time CFO – Free lance advisor in Finance, Corporate Structuring, and Operations
Chairman of the Supervisory Board and co-founder of Innate Pharma
University of Tokyo’s Graduate School of Frontier Sciences | AI Research Center
Avicenna Alliance for Predictive Medicine Secretary General
Head of the Institute for Systems Biology | Co-founder of Amgen
Director of the Centre d’Immunologie de Marseille-Luminy | Co-founder of Innate Pharma
François-Henri BOISSEL introducing NOVA at Labiotech Refresh 2017, Berlin.
Specify the optimal duration which helps to obtain the target effect, the dose that has to be used to maximize this effect. In other words, it’s to help us do the operations that are done today by a rather theoretical approach.
François-Henri BOISSEL introducing NOVA at 17th Biotech in Europe Forum – Sachs Associates
The human body contains 10 000 potential targets. that means that we are just at the begining and there is a huge of fields to be explored with the right tools to investigate in a capital efficient maner.